Literature DB >> 3293572

Hybridoma lupus autoantibodies can bind major cytoskeletal filaments in the absence of DNA-binding activity.

J L Senécal1, J Rauch.   

Abstract

A panel of 65 systemic lupus erythematosus (SLE) and 61 normal-derived human hybridoma auto-antibodies was studied for cytoskeletal reactivity, using an indirect immunofluorescence method. Reactivity with the cytoskeleton was expressed 3 times more frequently in the SLE-derived antibody group and included intermediate filaments, microfilaments, microtubules, and centrioles. By immunoblot analysis, the antigenic specificity of intermediate filament-reactive SLE hybridoma antibodies was not restricted to vimentin, but included cytokeratins and desmin. The antibodies were also studied for their DNA-binding, lupus anticoagulant, and rheumatoid factor activities. These autoantibody activities were expressed 3-5 times more frequently in the SLE-derived group. The ability to bind DNA was not a prerequisite for reactivity with intermediate filament proteins. Our findings suggest that there are at least 2 subsets of cytoskeletal-reactive hybridoma antibodies: those that recognize epitopes found only on cytoskeletal proteins, and those that recognize epitopes common to both DNA and certain cytoskeletal proteins. In addition, we hypothesize that there may be a third subset of antibodies that recognize a phosphate-containing moiety (phospholipid or phosphoprotein) associated with cytoskeletal filaments.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3293572     DOI: 10.1002/art.1780310707

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

1.  Antibodies to T- and L-isoforms of the cytoskeletal protein, fimbrin, in patients with systemic lupus erythematosus.

Authors:  E C De Mendonca Neto; A Kumar; N A Shadick; A M Michon; P Matsudaira; R B Eaton; P Kumar; P H Schur
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

Review 2.  Lessons about autoantibody specificity in systemic lupus erythematosus from animal models.

Authors:  D I Stott
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

3.  Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathy.

Authors:  Kevin E McElhanon; Nicholas Young; Jeffrey Hampton; Brian J Paleo; Thomas A Kwiatkowski; Eric X Beck; Ana Capati; Kyle Jablonski; Travis Gurney; Miguel A Lopez Perez; Rohit Aggarwal; Chester V Oddis; Wael N Jarjour; Noah Weisleder
Journal:  J Clin Invest       Date:  2020-08-03       Impact factor: 14.808

4.  Anti-alpha-internexin autoantibody from neuropsychiatric lupus induce cognitive damage via inhibiting axonal elongation and promote neuron apoptosis.

Authors:  Xiao-ye Lu; Xiao-xiang Chen; Li-dong Huang; Chang-qing Zhu; Yue-ying Gu; Shuang Ye
Journal:  PLoS One       Date:  2010-06-15       Impact factor: 3.240

5.  Monospecific but not polyreactive human hybridoma rheumatoid factors exhibit preferential binding specificities for IgG3 and IgG4.

Authors:  M M Newkirk; J Rauch
Journal:  Rheumatol Int       Date:  1994       Impact factor: 2.631

6.  Non-muscle myosin as target antigen for human autoantibodies in patients with hepatitis C virus-associated chronic liver diseases.

Authors:  C A von Mühlen; E K Chan; C L Peebles; H Imai; K Kiyosawa; E M Tan
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

Review 7.  Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.

Authors:  Olivier Benveniste; Werner Stenzel; David Hilton-Jones; Marco Sandri; Olivier Boyer; Baziel G M van Engelen
Journal:  Acta Neuropathol       Date:  2015-01-13       Impact factor: 17.088

8.  Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis.

Authors:  Arundhati Ray; Anthony A Amato; Elizabeth M Bradshaw; Kevin J Felice; Daniel B DiCapua; Jonathan M Goldstein; Ingrid E Lundberg; Richard J Nowak; Hidde L Ploegh; Eric Spooner; Qian Wu; Simon N Willis; Kevin C O'Connor
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.